pharmaphorum2d
FDA stifles Merck's cough drug gefapixant, asking for more data
The FDA has issued a complete response letter (CRL) to Merck & Co's gefapixant candidate for refractory chronic cough, delaying the programme and giving Bayer an opportunity to close the gap with ...
pharmaphorum15d
After cough drug setback, Merck partners Hyfe's tracking app
It's worth noting that the agreement has been forged a few months after Merck suffered a setback in its attempt to secure FDA approval for a potentially first-in-class drug for chronic cough ...
Zacks.com on MSN19d
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
Another company that was once ahead in the RCC drug race was Merck MRK, whose chronic cough drug, gefapixant, received two ...
The Lancet19d
Placebo responses in clinical trials of refractory chronic cough: mechanisms, challenges, and mitigation strategies
Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...